- Home
- MAS vs CNTX Comparison
MAS vs CNTX Comparison
Compare MAS & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAS | CNTX |
|---|---|---|
| Founded | 1929 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8B | 47.7M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MAS | CNTX |
|---|---|---|
| Price | $82.44 | $0.19 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 22 | 10 |
| Target Price | ★ $82.74 | $4.14 |
| AVG Volume (30 Days) | ★ 2.2M | 1.1M |
| Earning Date | 10-28-2026 | 11-17-2026 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | 2.66 | ★ 17.39 |
| EPS | ★ 3.81 | N/A |
| Revenue | ★ $7,562,000,000.00 | N/A |
| Revenue This Year | $1.98 | N/A |
| Revenue Next Year | $2.08 | N/A |
| P/E Ratio | $22.79 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $58.16 | $0.19 |
| 52 Week High | $87.86 | $3.62 |
Technical Indicators
Market Signals| Indicator | MAS | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.98 | 31.12 |
| Support Level | $65.99 | N/A |
| Resistance Level | $82.97 | $0.36 |
| Average True Range (ATR) | 2.81 | 0.02 |
| MACD | 0.75 | 0.00 |
| Stochastic Oscillator | 61.90 | 21.12 |
Price Performance
Historical ComparisonAbout MAS Masco Corporation
Masco is a global manufacturer of branded home improvement products, with a focus on plumbing fixtures (70% of revenue) and decorative architectural coatings (30% of revenue). The company primarily serves the repair and remodel market, with products such as faucets, showerheads, and paint sold through retail, wholesale, and e-commerce channels. Its portfolio includes well-known brands such as Delta, Hansgrohe, and Behr.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.